This inventor holds 1 USPTO granted patent and 6 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Oncopeptides Ab. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Innovations by Jakob Lindberg in the Treatment of AL Amyloidosis
Introduction
Jakob Lindberg is a notable inventor based in Stockholm, Sweden. He has made significant contributions to the field of medicine, particularly in the treatment of immunoglobulin light chain (AL) amyloidosis. His innovative approach has led to the development of a unique pharmaceutical formulation that addresses this challenging condition.
Latest Patents
Jakob Lindberg holds a patent for the treatment of AL amyloidosis with melflufen. The invention provides melflufen, or a salt thereof, for use in the treatment and/or prophylaxis of AL amyloidosis. This patent also includes dosage regimens and kits that are useful in the treatment and/or prophylaxis of the disease. Furthermore, it outlines methods for the treatment and/or prophylaxis of AL amyloidosis, as well as the uses of melflufen for the manufacture of a medicament aimed at treating this condition. He has 1 patent to his name.
Career Highlights
Jakob Lindberg is associated with Oncopeptides AB, a company that focuses on developing innovative therapies for cancer treatment. His work at Oncopeptides has been instrumental in advancing the understanding and treatment of AL amyloidosis.
Collaborations
Due to space constraints, the details of collaborations will not be included.
Conclusion
Jakob Lindberg's contributions to the treatment of AL amyloidosis through his patent on melflufen highlight his role as an innovative inventor in the medical field. His work continues to pave the way for advancements in therapeutic options for patients suffering from this condition.